QQQ   360.68 (-1.06%)
AAPL   175.39 (-0.06%)
MSFT   321.94 (+0.36%)
META   300.00 (+0.11%)
GOOGL   131.79 (-1.46%)
AMZN   130.88 (-3.26%)
TSLA   258.85 (-1.42%)
NVDA   414.75 (-1.81%)
NIO   8.54 (-3.17%)
BABA   84.46 (-1.49%)
AMD   96.96 (-3.37%)
T   15.35 (-1.29%)
F   12.25 (-0.89%)
MU   68.76 (-1.32%)
CGC   0.82 (-6.32%)
GE   113.82 (-0.90%)
DIS   83.33 (+0.93%)
AMC   7.86 (-3.68%)
PFE   33.03 (-1.75%)
PYPL   58.88 (-3.25%)
NFLX   387.17 (+0.23%)
QQQ   360.68 (-1.06%)
AAPL   175.39 (-0.06%)
MSFT   321.94 (+0.36%)
META   300.00 (+0.11%)
GOOGL   131.79 (-1.46%)
AMZN   130.88 (-3.26%)
TSLA   258.85 (-1.42%)
NVDA   414.75 (-1.81%)
NIO   8.54 (-3.17%)
BABA   84.46 (-1.49%)
AMD   96.96 (-3.37%)
T   15.35 (-1.29%)
F   12.25 (-0.89%)
MU   68.76 (-1.32%)
CGC   0.82 (-6.32%)
GE   113.82 (-0.90%)
DIS   83.33 (+0.93%)
AMC   7.86 (-3.68%)
PFE   33.03 (-1.75%)
PYPL   58.88 (-3.25%)
NFLX   387.17 (+0.23%)
QQQ   360.68 (-1.06%)
AAPL   175.39 (-0.06%)
MSFT   321.94 (+0.36%)
META   300.00 (+0.11%)
GOOGL   131.79 (-1.46%)
AMZN   130.88 (-3.26%)
TSLA   258.85 (-1.42%)
NVDA   414.75 (-1.81%)
NIO   8.54 (-3.17%)
BABA   84.46 (-1.49%)
AMD   96.96 (-3.37%)
T   15.35 (-1.29%)
F   12.25 (-0.89%)
MU   68.76 (-1.32%)
CGC   0.82 (-6.32%)
GE   113.82 (-0.90%)
DIS   83.33 (+0.93%)
AMC   7.86 (-3.68%)
PFE   33.03 (-1.75%)
PYPL   58.88 (-3.25%)
NFLX   387.17 (+0.23%)
QQQ   360.68 (-1.06%)
AAPL   175.39 (-0.06%)
MSFT   321.94 (+0.36%)
META   300.00 (+0.11%)
GOOGL   131.79 (-1.46%)
AMZN   130.88 (-3.26%)
TSLA   258.85 (-1.42%)
NVDA   414.75 (-1.81%)
NIO   8.54 (-3.17%)
BABA   84.46 (-1.49%)
AMD   96.96 (-3.37%)
T   15.35 (-1.29%)
F   12.25 (-0.89%)
MU   68.76 (-1.32%)
CGC   0.82 (-6.32%)
GE   113.82 (-0.90%)
DIS   83.33 (+0.93%)
AMC   7.86 (-3.68%)
PFE   33.03 (-1.75%)
PYPL   58.88 (-3.25%)
NFLX   387.17 (+0.23%)
NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$17.25
-0.16 (-0.92%)
(As of 01:58 PM ET)
Compare
Today's Range
$16.96
▼
$17.36
50-Day Range
$17.41
▼
$23.88
52-Week Range
$16.95
▼
$39.85
Volume
159,523 shs
Average Volume
478,881 shs
Market Capitalization
$955.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
177.9% Upside
$48.10 Price Target
Short Interest
Bearish
12.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Kymera Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.55) to ($3.26) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

786th out of 962 stocks

Biological Products, Except Diagnostic Industry

127th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

KYMR stock logo

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Price History

KYMR Stock News Headlines

September 18, 2023 | finance.yahoo.com
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
September 11, 2023 | americanbankingnews.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts
September 21, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
August 31, 2023 | finance.yahoo.com
Industry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19%
August 30, 2023 | msn.com
Morgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendation
August 29, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Kymera Therapeutics
August 28, 2023 | finance.yahoo.com
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 9, 2023 | msn.com
Kymera Therapeutics - Need More Developments Before Making This A Buy
September 21, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
August 8, 2023 | msn.com
Stifel Maintains Kymera Therapeutics (KYMR) Buy Recommendation
August 7, 2023 | markets.businessinsider.com
Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
August 6, 2023 | seekingalpha.com
Kymera Therapeutics: A Status Update
August 4, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
August 4, 2023 | msn.com
HC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendation
August 4, 2023 | markets.businessinsider.com
Expert Ratings for Kymera Therapeutics
August 3, 2023 | finance.yahoo.com
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
July 27, 2023 | finance.yahoo.com
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
July 9, 2023 | finance.yahoo.com
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
July 1, 2023 | msn.com
Truist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation
June 22, 2023 | seekingalpha.com
FDA grants orphan drug status to Kymera blood cancer drug KT-253
June 22, 2023 | finance.yahoo.com
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
June 21, 2023 | benzinga.com
Board Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Shares
June 16, 2023 | fool.com
Kymera Therapeutics (NASDAQ: KYMR)
June 15, 2023 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Kymera Therapeutics
June 15, 2023 | markets.businessinsider.com
Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus
June 14, 2023 | finance.yahoo.com
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 13, 2023 | msn.com
Kymera climbs on data updates for three drug programs
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings
8/03/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KYMR
CUSIP
N/A
CIK
1815442
Web
www.kymeratx.com
Phone
857-285-5300
Fax
N/A
Employees
181
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.10
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+176.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-154,810,000.00
Net Margins
-305.01%
Pretax Margin
-305.01%
Return on Equity
-33.17%
Return on Assets
-25.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.06
Quick Ratio
7.06

Sales & Book Value

Annual Sales
$51.67 million
Price / Sales
18.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.93 per share
Price / Book
1.95

Miscellaneous

Outstanding Shares
55,412,000
Free Float
46,175,000
Market Cap
$964.72 million
Optionable
Not Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Bruce L. Booth D.Phil. (Age 49)
    DPHIL, Ph.D., Co-Founder & Chairman
    Comp: $79.19k
  • Dr. Nello Mainolfi M.D. (Age 45)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $975.2k
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jared A. Gollob M.D. (Age 58)
    Chief Medical Officer
    Comp: $637.81k
  • Dr. Jeremy G. Chadwick Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Michael J. Todisco (Age 58)
    VP of Accounting & Fin.
  • Mr. Vijay Sabesan (Age 51)
    Sr. VP of Technical Operations
  • Ms. Justine E. Koenigsberg
    VP of Investor Relations
  • Ms. Ellen V. Chiniara Esq. (Age 64)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Melissa Brody
    VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.

What is Kymera Therapeutics' stock price forecast for 2023?

9 brokers have issued 1-year price objectives for Kymera Therapeutics' stock. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's stock price to reach $48.10 in the next twelve months. This suggests a possible upside of 176.3% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.

How have KYMR shares performed in 2023?

Kymera Therapeutics' stock was trading at $24.96 at the beginning of the year. Since then, KYMR shares have decreased by 30.2% and is now trading at $17.41.
View the best growth stocks for 2023 here.

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KYMR earnings forecast.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.70) by $0.03. The business earned $16.51 million during the quarter, compared to the consensus estimate of $13.93 million. Kymera Therapeutics had a negative net margin of 305.01% and a negative trailing twelve-month return on equity of 33.17%. The firm's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.78) EPS.

What ETFs hold Kymera Therapeutics' stock?

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.82%), State Street Corp (4.73%), Rock Springs Capital Management LP (2.68%), Wasatch Advisors LP (2.16%), Dimensional Fund Advisors LP (1.52%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $17.41.

How much money does Kymera Therapeutics make?

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $964.72 million and generates $51.67 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Kymera Therapeutics have?

The company employs 181 workers across the globe.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -